Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Effects of Switching Kaletra to Boosted Reyataz

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously diagnosed HIV infection~2. Age between 18-65 years~3. Stable antiviral regimen containing at least 2 nucleoside reverse transcriptase inhibitors (NRTI's) and LPV/r for ³ 6 mos~4. CD4 count \> 400 cell/mm3~5. Metabolic complication as indicated by one or more of hyperinsulinemia (fasting insulin \>= 15 mIU/ml), hypercholesteremia (fasting total cholesterol \>= 200 mg/dL), hypertriglyceridemia (fasting triglycerides \>= 150 mg/dL), or treatment with a lipid lowering medication.~Exclusion Criteria:~1. Hemoglobin \< 11.0 g/dL~2. History of Diabetes Mellitus~3. Currently on medication for Diabetes~4. Therapy with glucocorticoid, growth hormone or other anabolic agents currently or within the past 3 months~5. Current substance abuse, including alcohol, cocaine and/or heroin~6. Any contraindication to ATV/r or known allergy to ATV~7. Concurrent therapy with: Bepridil; cisapride; ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine); indinavir; irinotecan; lovastatin; midazolam; pimozide; proton pump inhibitors (esomeprazole, lansoprazole, omeprazole); rifampin; simvastatin; St John's wort; or triazolam~8. New or serious opportunistic infection in the past 3 months~9. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
- 2 (Type: ACTIVE_COMPARATOR): Kaletra (pre-study dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).